Therapies for patients with CLL with available data on patients with BTKi resistance mutations
| Treatment . | Study description . | No. of patients with documented BTKi resistance mutations . | No. of ORR in patients with BTKi resistance mutations (%) . | No. of median PFS in patients with BTKi resistance mutations (95% CI) . | Clinical trial reference . |
|---|---|---|---|---|---|
| Venetoclax | Prospective phase 2 | 17 | 12 (71) | 21.9 (4.4-NR) | 34 |
| Duvelisib | Prospective phase 1 | 3 | 0 (0) | NA | 79 |
| ARQ-531 | Prospective phase 1 | 9* | 8 (89) | NA | 80 |
| LOXO-305 | Prospective phase 1 | 24† | 17 (70) | NA | .81 |
| Treatment . | Study description . | No. of patients with documented BTKi resistance mutations . | No. of ORR in patients with BTKi resistance mutations (%) . | No. of median PFS in patients with BTKi resistance mutations (95% CI) . | Clinical trial reference . |
|---|---|---|---|---|---|
| Venetoclax | Prospective phase 2 | 17 | 12 (71) | 21.9 (4.4-NR) | 34 |
| Duvelisib | Prospective phase 1 | 3 | 0 (0) | NA | 79 |
| ARQ-531 | Prospective phase 1 | 9* | 8 (89) | NA | 80 |
| LOXO-305 | Prospective phase 1 | 24† | 17 (70) | NA | .81 |
NA, not available; NR, not reached; ORR, overall response rate.
No. of patients with BTKi-resistant mutations that were treated at the recommended dose of 65 mg daily.
Twenty-four patients on study had a BTK C481S mutation, and 4 additional patients had a PLC2 mutation, but response data were not available for this population.